Subject
General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology
Reference7 articles.
1. Wei JC , Kim TH , Kishimoto M , et al . Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomized, placebo-controlled, phase 3 trial. Ann Rheum Dis 2021.doi:10.1136/annrheumdis-2020-219406
2. Zhao Y , Huang J-X . Correspondence on “Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomized, placebo-controlled, phase 3 trial”. Ann Rheum Dis.doi:10.1136/annrheumdis-2021-220759
3. FDA . SILIQ™(brodalumab) injection, for subcutaneous use. Valeant pharmaceuticals North America LLC, Bridgewater, NJ 08807, USA, 2017. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761032lbl.pdf [Accessed 02 Jun 2019].
4. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
5. Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献